Purchase this article with an account.
G. Alvarez–Rivera, J.L. Guerrero–Naranjo, A. Perez–Reguera, D. Moreno–Paramo, E. Reyna, M. Hernandez, A. Solis, M. Abraham, E. Romo, H. Quiroz–Mercado; Is Intravitreous Bevacizumab (Avastin) an Effective Treatment for Venous Occlusions? . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4254.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate visual results and macular thicknes changes measured by optical coherence tomography (OCT) in patients diagnosed with venous occlusions treated with intravitreous Bevacizumab.
A pilot study. 10 patients were include (4 with central vein occlusion and 6 with branch vein occlusion). With previous written consentiment, we performed full opthalmologic examination with biomicroscopy, best corrected visual acuity, fluorescein angiography, OCT, and measure intraocular pressure, full fisical examination including sistemic presure. After asepsia and antiseptical techniques we aplied to selected patients 0.1ml. (125mg.) intraocular bevacizumab via pars plana.
Intravitreous bevacizumab inyection may be an efficent, safe, and low–cost treatment in patients with venous occlusions.
This PDF is available to Subscribers Only